Abstract 546P
Background
Malignant pleural mesothelioma (MPM) is an asbestos-related fatal malignant neoplasm. Although combination therapy of ipilimumab plus nivolumab has proven to bring about a better outcome in patients with MPM, long-term survival remains unsatisfactory. To further improve the prognosis, developing a novel treatment strategy to maximize the antitumor effect of ICI is a pressing issue. We examined whether nintedanib, an antiangiogenic agent, could augment the antitumor effect of anti-PD-1 antibody (Ab).
Methods
We established subcutaneous mice mesothelioma allograft model. Mice were treated either with vehicle, anti-PD-1 Ab, nintedanib or anti-PD-1 Ab plus nintedanib. Tumor size was routinely measured with a caliper. Mice were euthanized before they became moribund, and allografts were collected for histological analyses. Angiogenesis and infiltrating immune cells were assessed by immunohistochemistry (IHC). We further performed ex vivo study using bone marrow-derived macrophages (BMDMs) to elucidate the antitumor mechanism of the combination therapy of anti-PD-1 Ab plus nintedanib.
Results
Nintedanib significantly suppressed the growth of mesothelioma allografts. Combination therapy with anti-PD-1 Ab plus nintedanib reduced tumor burden more dramatically compared with nintedanib monotherapy. IHC analyses revealed that nintedanib not only inhibited angiogenesis but also decreased the infiltration of tumor-associated macrophages (TAMs). Moreover, ex vivo study using BMDMs showed that nintedanib could polarize TAMs from M2 to M1 phenotype. Thus, nintedanib could suppress protumor activity of TAMs both numerically and functionally. On the other hand, nintedanib upregulated the expression of PD-1 and PD-L1 in BMDMs and mesothelioma cells, respectively, and impaired the phagocytic activity of BMDMs against mesothelioma cells. Co-administration of anti-PD-1 Ab may reactivate phagocytic activity of BMDMs by disrupting nintedanib-induced immunosuppressive signal.
Conclusions
Combination therapy of anti-PD-1 Ab plus nintedanib exerts synergistic antitumor activity and can become a novel therapeutic option for patients with MPM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Minami: Financial Interests, Institutional, Research Grant: Nippon Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract